Sebastian Giebel Selected Research

Cyclophosphamide (Cytoxan)

3/2024	Haploidentical stem cell donor choice for patients with acute myeloid leukemia: A study from the ALWP of the EBMT.
12/2023	Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
12/2023	Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
3/2023	Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis.
1/2023	Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
1/2023	Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT.
1/2023	Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT.
12/2022	Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT.
11/2022	Posttransplant cyclophosphamide-based anti-graft-vs-host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen-mismatched unrelated donors versus haploidentical donors: A study on behalf of the ALWP of the EBMT.
1/2022	Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sebastian Giebel Research Topics

Disease

68	Leukemia 05/2024 - 10/2006
50	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2023 - 02/2002
35	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2024 - 02/2008
30	Graft vs Host Disease (Graft-Versus-Host Disease) 03/2024 - 08/2003
14	Neoplasms (Cancer) 01/2024 - 08/2003
12	Lymphoma (Lymphomas) 12/2023 - 08/2003
9	Multiple Myeloma 01/2021 - 06/2011
7	Infections 01/2023 - 02/2002
6	Hematologic Neoplasms (Hematological Malignancy) 02/2024 - 10/2009
6	Bronchiolitis Obliterans Syndrome 01/2021 - 01/2006
5	Residual Neoplasm 05/2024 - 06/2016
5	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 07/2021 - 01/2006
4	Hodgkin Disease (Hodgkin's Disease) 12/2023 - 01/2021
4	Philadelphia Chromosome 01/2021 - 10/2016
3	Mycosis Fungoides 01/2023 - 04/2015
3	Pathologic Complete Response 12/2022 - 07/2010
3	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 09/2022 - 02/2012
3	Neutropenia 01/2022 - 06/2006
3	Rheumatoid Arthritis 08/2010 - 01/2002
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 06/2006 - 01/2006
2	COVID-19 01/2023 - 01/2021
2	Thrombocytopenia (Thrombopenia) 01/2022 - 01/2021
2	Disease Progression 07/2021 - 06/2014
2	Thrombosis (Thrombus) 10/2020 - 11/2008
2	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 10/2020 - 01/2005
2	Inflammation (Inflammations) 10/2020 - 01/2002
2	Systemic Scleroderma (Systemic Sclerosis) 12/2017 - 08/2003
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2016 - 08/2003
1	Diarrhea 03/2024
1	Clostridium Infections 03/2024
1	Orbital lymphoma 01/2023
1	Bone Diseases (Bone Disease) 01/2023
1	Waldenstrom Macroglobulinemia (Macroglobulinemia) 07/2022
1	Viremia 02/2022
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2022
1	Sezary Syndrome (Sezary Erythroderma) 04/2021
1	Anemia 01/2021

Drug/Important Bio-Agent (IBA)

21	Cyclophosphamide (Cytoxan)FDA LinkGeneric 03/2024 - 01/2006
15	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2022 - 10/2006
11	fludarabineIBA 01/2023 - 10/2006
9	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 12/2023 - 08/2003
7	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2019 - 02/2002
6	Busulfan (Busulfex)FDA Link 01/2023 - 01/2021
6	Cladribine FDA LinkGeneric 08/2021 - 02/2008
4	Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric 10/2023 - 01/2017
4	treosulfanIBA 12/2022 - 01/2006
4	Etoposide (VP 16)FDA LinkGeneric 01/2022 - 01/2018
4	Dexamethasone (Maxidex)FDA LinkGeneric 07/2021 - 01/2016
4	Tyrosine Kinase InhibitorsIBA 01/2021 - 10/2016
3	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 08/2003
3	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2022 - 08/2003
3	Bendamustine Hydrochloride FDA Link 07/2021 - 10/2019
3	InterferonsIBA 04/2021 - 06/2006
3	Melphalan (Alkeran)FDA LinkGeneric 01/2021 - 01/2018
3	SteroidsIBA 02/2020 - 01/2005
3	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2020 - 10/2006
2	Azacitidine (5 Azacytidine)FDA Link 07/2021 - 01/2019
2	Gemcitabine FDA Link 07/2021 - 07/2021
2	Carmustine (FIVB)FDA Link 01/2021 - 01/2018
2	Rituximab (Mabthera)FDA Link 10/2019 - 01/2018
2	LigandsIBA 06/2014 - 08/2003
2	Daunorubicin (Cerubidine)FDA LinkGeneric 07/2012 - 02/2010
2	Prednisolone (Predate)FDA LinkGeneric 01/2006 - 01/2005
1	thymoglobulin FDA Link 12/2023
1	molnupiravirIBA 01/2023
1	Antiviral Agents (Antivirals)IBA 01/2023
1	HLA Antigens (Human Leukocyte Antigens)IBA 11/2022
1	MicroRNAs (MicroRNA)IBA 09/2022
1	RNA (Ribonucleic Acid)IBA 09/2022
1	6-bromo-2-naphthyl sulfate (BNS)IBA 07/2022
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022
1	Ifosfamide FDA LinkGeneric 01/2022
1	itacitinibIBA 01/2022
1	Amsacrine (AMSA)IBA 01/2022
1	ofatumumab FDA Link 01/2022
1	DNA (Deoxyribonucleic Acid)IBA 11/2021
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 11/2021
1	Therapeutic UsesIBA 01/2021
1	GlucocorticoidsIBA 01/2021
1	ruxolitinibIBA 01/2021
1	daratumumabIBA 01/2021
1	Chimeric Antigen ReceptorsIBA 01/2021
1	Monoclonal AntibodiesIBA 01/2021

Therapy/Procedure

56	Transplantation 05/2024 - 01/2005
43	Hematopoietic Stem Cell Transplantation 02/2024 - 08/2003
39	Cell Transplantation 03/2024 - 01/2006
32	Stem Cell Transplantation 05/2024 - 08/2003
23	Drug Therapy (Chemotherapy) 11/2023 - 02/2002
22	Therapeutics 02/2024 - 02/2002
4	Homologous Transplantation 01/2023 - 01/2017
4	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 12/2022 - 01/2017
4	Haploidentical Transplantation 01/2021 - 11/2017
3	Immunotherapy 05/2024 - 01/2021
3	Radiotherapy 10/2020 - 04/2015
3	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2018 - 01/2005
2	Salvage Therapy 01/2022 - 07/2021
2	Hematopoietic Stem Cell Mobilization 01/2016 - 06/2011
1	Traction 01/2021
1	Donor Selection 01/2021
1	Investigational Therapies (Experimental Therapy) 01/2021